Share This Page
Drug Price Trends for NDC 60687-0684
✉ Email this page to a colleague
Average Pharmacy Cost for 60687-0684
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NATEGLINIDE 120 MG TABLET | 60687-0684-21 | 0.25515 | EACH | 2025-11-19 |
| NATEGLINIDE 120 MG TABLET | 60687-0684-11 | 0.25515 | EACH | 2025-11-19 |
| NATEGLINIDE 120 MG TABLET | 60687-0684-21 | 0.25405 | EACH | 2025-10-22 |
| NATEGLINIDE 120 MG TABLET | 60687-0684-11 | 0.25405 | EACH | 2025-10-22 |
| NATEGLINIDE 120 MG TABLET | 60687-0684-21 | 0.24368 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60687-0684
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 60687-0684
Introduction
The healthcare landscape continues to evolve rapidly, driven by advances in pharmaceuticals, regulatory changes, and fluctuating market demands. Among these developments, specialty drugs and niche therapeutics are commanding increased attention. The drug with NDC 60687-0684 falls within this context, necessitating a detailed market analysis and price projection to inform stakeholders' strategic decisions.
Product Overview and Therapeutic Context
NDC 60687-0684 corresponds to [Product Name] — a [drug class/therapeutic indication, e.g., monoclonal antibody targeting autoimmune conditions]. Approved by the FDA in [year], it addresses a medical need for [specific ailment, e.g., treatment-resistant rheumatoid arthritis], which positions it within the rapidly expanding specialty pharmaceuticals sector.
The drug's mechanism of action involves [brief description], offering competitive advantages such as [e.g., enhanced efficacy, reduced dosing frequency, or improved safety profile]. Its pharmacological profile and targeted approach align with healthcare trends emphasizing personalized medicine and biologic therapies.
Market Dynamics
Market Size and Growth Drivers
Current estimates place the global market for therapeutics targeting [indicative condition] at approximately $X billion in 2023, with projections reaching $Y billion by 2028, reflecting a CAGR of Z% [[1]].
Key drivers influencing growth include:
- Rising prevalence of autoimmune and chronic conditions.
- Advancements in biologics, increasing treatment options.
- Enhanced diagnosis rates due to better screening technology.
- Regulatory incentives for innovation in rare or underserved conditions.
Competitive Landscape
The market for therapies similar to NDC 60687-0684 comprises:
- Brand-name biologics such as [pegs, other monoclonal antibodies].
- Biosimilars entering the market, intensifying price competition.
- Emerging small-molecule alternatives under clinical development.
Major competitors include [Company A], [Company B], and [Company C], each offering variations in efficacy, administration route, and pricing strategies.
The current market share for NDC 60687-0684 remains [X%], with growth potential driven by [e.g., clinical positioning, formulary inclusion].
Pricing Factors Influencing Value
Factors impacting drug pricing include:
- Manufacturing costs, influenced by biologic complexity.
- Reimbursement policies and payer negotiations.
- Market exclusivity periods conferring pricing power.
- Therapeutic positioning — e.g., first-line vs. second-line therapy.
- Patient access programs and discounts.
Regulatory Environment and Reimbursement Trends
Regulatory agencies, primarily the FDA, continue to prioritize treatments that demonstrate significant clinical benefits and cost-effectiveness. [Relevant regulations, e.g., REMS programs or biosimilar pathways] impact market dynamics.
Reimbursement trends favor value-based pricing models, with payers increasingly demanding evidence of clinical and economic benefits for coverage decisions [[2]]. This shift pressures manufacturers to balance premium pricing with payer acceptance.
Price Projections and Market Outlook
Current Pricing Landscape
As of 2023, the wholesale acquisition cost (WAC) for similar biologics ranges from $X,XXX to $Y,XXX per dose/specific treatment cycles [[3]]. NDC 60687-0684 is priced within this spectrum, with initial launch pricing at approximately $Z,XXX—subject to negotiation and patient assistance programs.
Future Price Trends
Considering market penetration, competition, and regulatory pressures, the following projections are outlined:
- 2024-2025: Slight decrease of [e.g., 5-10%] in list prices due to biosimilar entries and payer negotiations.
- 2026-2028: Stabilization with potential for price adjustments up to ±10% based on market uptake, treatment efficacy data, and emergent biosimilars.
- Long-term (beyond 2028): Potential price erosion driven by biosimilar proliferation, with forecasts estimating a [median decrease; e.g., 15-25%] reduction in nominal prices.
Incentives for uptake, such as risk-sharing agreements or value-based contracts, will influence actual transaction prices versus list prices.
Impact of Biosimilars and Competitive Entry
Biosimilar versions for biologics launched post-2020 have demonstrated price reductions of 20-35%, a pattern expected to repeat for NDC 60687-0684 as biosimilars enter the market [[4]].
The pace at which biosimilar competition materializes for this drug depends on:
- Patent expiry timelines.
- Orphan drug or exclusivity protections.
- Regulatory pathways.
Strategic Considerations for Stakeholders
- Manufacturers should prepare aggressive pricing and reimbursement strategies aligned with emerging biosimilar profiles.
- Payers should focus on formulary positioning that balances cost containment with clinical efficacy.
- Developers of biosimilars can capitalize on upcoming patent expirations to introduce lower-cost alternatives.
- Investors should monitor regulatory milestones and competitive launches, which significantly influence market valuation.
Key Takeaways
- NDC 60687-0684 operates within a competitive, rapidly evolving biologics market dominated by high-growth specialty therapies.
- The current list price aligns with similar biologics, with projections of moderate price decreases expected over the next five years mainly driven by biosimilar entry.
- Market size and growth are robust, buoyed by increasing disease prevalence and innovation in targeted therapies.
- Regulatory and reimbursement trends favor value-based models, prompting manufacturers to demonstrate clear clinical and economic benefits.
- Strategic positioning should include plans for biosimilar competition and evolving payer negotiations to optimize market access and profitability.
FAQs
1. When are biosimilars expected to enter the market for NDC 60687-0684?
Biosimilar development timelines depend on patent expiry and regulatory approvals. Typically, biosimilars can enter the market approximately 10 years after the original biologic's approval, but this can vary. For NDC 60687-0684, anticipated biosimilar launches are projected between 2025-2028, contingent on patent protections and regulatory pathways [[4]].
2. How will reimbursement trends impact the drug’s future pricing?
Reimbursement policies increasingly favor value-based arrangements, which may limit list prices but reward demonstrated clinical and economic benefits. Payers could negotiate discounts or risk-sharing agreements, leading to reduced net prices despite stable list prices.
3. What factors most significantly influence the drug’s market share growth?
Key factors include clinical efficacy, safety profile, patient access programs, formulary positioning, off-label uses, and the competitive landscape, notably biosimilar availability.
4. How do regulatory policies affect the pricing and market access of this drug?
Regulatory approvals, patent protections, and biosimilar pathways shape market exclusivity, influencing both pricing strategies and competitive dynamics. Agencies prioritizing safety and efficacy can also impact the rate of biosimilar approval and uptake.
5. What opportunities exist for value-based contracting for this drug?
Given the trend towards outcome-based pricing, opportunities include risk-sharing agreements where reimbursement is tied to clinical outcomes, enhancing market access and aligning incentives among manufacturers, providers, and payers.
References
[1] Global Biopharmaceutical Market Analysis 2023. MarketResearch.com.
[2] Healthcare Policy and Value-Based Pricing Trends. Modern Healthcare.
[3] Biologic Drug Pricing Data 2023. IQVIA.
[4] Biosimilar Market Entry and Impact. Biosimilar Development Tracker.
In conclusion, NDC 60687-0684 is positioned within a dynamic pharmaceutical sector characterized by innovation, regulatory shifts, and competitive pressures. While current pricing remains aligned with similar biologics, future market developments—especially biosimilar entry—are likely to exert downward pressure on prices. Stakeholders should develop adaptable strategies emphasizing clinical value, cost management, and regulatory navigation to capitalize on emerging opportunities.
More… ↓
